New Cancer Therapies: Implications for the Perioperative Period

Abstract

Purpose of Review Cancer is on the rise. Standing on verge of exciting discoveries, research is being translated into therapies that are being widely administered to patients. Providing a hope for cure, where none existed before. This new body of knowledge has come from a better understanding of cancer genetics, molecular and sub molecular behavior, and understanding of cancergenerated cellular environments. These have led to development of immunotherapy and its many sub-genres, improvement and introduction of new radiation technologies, and decreasing toxicities of existing chemotherapies. Recent Findings The purpose of this review is to have a summary look at this huge landscape of cancer therapy. Specially looking at toxicities that an anesthesiologist should be familiar with while providing perioperative care for these patients, complications like tumor lysis syndrome, cytokine release syndromes, Kounis syndrome, myocarditis, encephalopathies, and pituitary failure need to be kept in mind. Summary One should be knowledgeable about these therapies and approach these patients with a high index of suspicion. Anesthesiologists will need to refine preoperative assessment with appropriate testing and intraoperative and postoperative management in collaboration with oncologists, while involving the expertise of internists, cardiologist, and endocrinologists in helping assess and manage these patients in the perioperative period. Keywords Anesthesia assessment in cancer patients. Perioperative implications of cancer therapy. New cancer therapies, side effects, and management in perioperative period. Immunotherapy, mechanism of actions, and side effects. Side effects This article is part of the Topical Collection on Cancer Anesthesia

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

“…Tumor cells utilize immune checkpoints such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) to evade T-cell recognition and immune response. Immune checkpoint inhibitors (ICI), while often efficacious for anti-tumor response, yield a myriad of toxicities and autoimmune reactions that limit their generalizability and application [ 8 •]. Ipilimumab, an antibody against CTLA-4, is approved for use against metastatic melanoma, renal cell carcinoma, and colorectal cancer.…”

Synergistic Fabrication of Dose–Response Chitosan/Dextran/β-Glycerophosphate Injectable Hydrogel as Cell Delivery Carrier for Cardiac Healing After Acute Myocardial Infarction

“…Heart failure, impulsive death, privation of left ventricular function, and ischemic heart diseases are the highly complicated exposure arrived by AMI. 1 - 4 Additionally, disruption of homeostatic balance causes series of successive events like ventricular stiffness, inflammatory effects, necrosis, apoptosis, remodeling that leads to forming scar and altered contractility in heart muscles. Surgical and medical approaches like percutaneous coronary intervention and pharmacotherapies can significantly enroll their contribution toward appalling effects of AMI.…”